(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Kidney Cancer Session II. Dr Mark Ball discussed Biomarkers and Clinical Predictors in Renal Cell Carcinoma (RCC).
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Kidney Cancer Session II. Dr Naomi Haas presented an update on Neoadjuvant therapy trials in renal cell carcinoma (RCC).
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Session II. Dr. Trinity Bivalacqua discussed Sexual Dysfunction and Radical Cystectomy.
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Joseph A Smith, Jr. Mentorship Award Lecture. by Dr. Christopher Kane.
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Session II. Dr. Mamta Parikh discussed Emerging Therapeutics: Combination Therapy in the Neoadjuvant Setting for Bladder Cancer.
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX between December 3rd – 6th, 2024 was host to a bladder cancer poster session. Dr. Vikram Narayan presented the results of ABLE-32, a randomized, controlled, phase IIIB clinical trial of Nadofarogene Firadenovec-vcng versus observation in patients with intermediate-risk, non-muscle invasive bladder cancer (NMIBC).
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr. Behfar Ehdaie discussing the role of salvage radical prostatectomy.
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr. Himanshu Nagar discussing the role of salvage radiotherapy. A solitary loco-regional recurrence on PSMA PET/CT for PSA recurrence is common, seen in 17%-71% of cases after primary radiotherapy:
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr. Kara Watts discussing the role of salvage focal ablation. Currently, ~90-95% of men with biochemical recurrence after radiotherapy are managed with ADT alone.
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a presentation by Dr. Michael Leapman discussing sustainability in prostate cancer care. Despite increased pledges and targets to address climate change, current policies still leave the world on course for a ~2.7 °C end-of-century global warming above pre-industrial levels—far from the ambitious aim of the Paris Agreement to limit global warming to 1.5 °C:
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a presentation by Dr. Ganesh Palapattu discussing the biology of cancer metastases. Dr. Palapattu started his presentation by emphasizing that the reason we should care about the biology of cancer metastasis is that we may be able to improve risk stratification of localized disease and that we also may be able to improve therapy for advanced disease.
(UroToday.com) At the 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX between December 3rd – 6th, 2024, Dr. Seth Lerner received the prestigious Huggins Medal award from the SUO committee.
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Session II. Dr. Hadley Wyre discussed how to prevent and manage Long Term Complications of Radical Cystectomy.
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX between December 3rd – 6th, 2024 was host to a bladder cancer poster session. Dr. Roger Li presented the results of an exploratory, ad hoc analysis of the phase II KEYNOTE-057 trial evaluating the post-treatment outcomes of patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk (HR), non-muscle invasive bladder cancer (NMIBC) who experienced a ‘non-response’ to pembrolizumab monotherapy.
(UroToday.com) The 2024 SUO annual meeting included a session on BCG unresponsive non muscle invasive bladder cancer (NMIBC), featuring a presentation by Dr. Eugene Pietzak III discussing our current options for BCG unresponsive NMIBC. The BCG unresponsive definition based on expert opinion is as follows:
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a late breaking abstract presentation by Dr. Tobias Nordstrom discussing the STHLM3 trial and biochemical recurrence after radical prostatectomy and whether we are missing aggressive prostate cancer with PSA screening alone.
(UroToday.com) The 2024 SUO annual meeting included a health services session, featuring a presentation by Dr. Juan Andino discussing public policy and future directions of telehealth and cancer. The workforce challenges in urology today are highlighted by the AUA’s number of urologists practicing per county:
(UroToday.com) The 2024 SUO annual meeting included a health services session, featuring a presentation by Dr. Ann Raldow discussing novel approaches to radiotherapy to reduce patient burden. Frequent visits for radiotherapy significantly impact patients’ quality of life due to the associated time burden, loss of income, and increased expenses such as gas and parking costs. Moreover, radiotherapy side effects, including urinary, bowel, and sexual dysfunction, have a lasting effect on long-term well-being. Addressing these challenges and reducing the physical, financial, and emotional burdens of treatment can enhance patient adherence and satisfaction. Importantly, newer radiation approaches are transforming how cancer is treated, leading to shorter, more efficient treatments with fewer side effects and greater convenience for patients.
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a presentation by Dr. Daniela Wittmann discussing sexual satisfaction despite sexual dysfunction. Dr. Wittmann started her presentation by highlighting what we most associate with sex: experience of pleasure, feeling of intense satisfaction, intimate connection with a partner, and sharing pleasure. However, she notes that none of these absolutely require intact sexual function.
(UroToday.com) The 2024 SUO annual meeting included a urothelial carcinoma session, featuring a presentation by Dr. Vitaly Margulis discussing the ENLIGHTED phase 3 study assessing the efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) for the treatment of low-grade upper tract urothelial carcinoma. Padeliporfin VTP is a combination product:
